[Pubmed] Serum utrophin levels in patients with myasthenia gravis: an exploratory study
-
RSS-Bot
Auteur du sujet - Ami(e) de Diamant

- Messages : 6516
- Enregistré le : 31 mai 2020 09:57
- 6
- Zodiaque :
- Âge : 22
- Contact :
[Pubmed] Serum utrophin levels in patients with myasthenia gravis: an exploratory study
Neurol Res. 2026 Oct 13:1-8. doi: 10.1080/01616412.2026.2746411. Online ahead of print.
ABSTRACT
OBJECTIVES: The role of utrophin, a protein expressed at neuromuscular junctions, remains unclear in myasthenia gravis (MG). This study aimed to investigate serum utrophin levels in immunotherapy-naïve patients with different MG subtypes and evaluate changes before and after immunotherapy initiation.
METHODS: We measured serum utrophin levels in immunotherapy-naïve MG patients (n = 39), including acetylcholine receptor (AChR) antibody-positive MG (AChR-MG) (n = 30; ocular type: n = 10, generalized type: n = 20) and muscle-specific tyrosine kinase antibody-positive MG (MuSK-MG) (n = 9; all generalized type) patients and healthy controls (HCs) (n = 21). We analyzed relationships between serum utrophin levels, clinical parameters, and antibody levels. In generalized AChR-MG, serum utrophin levels were measured before and after immunotherapy.
RESULTS: Median serum utrophin levels tended to be higher in patients with MG than in HCs (34.0 vs. 13.8 ng/mL; Hodges-Lehmann estimate, 7.04 ng/mL; 95% confidence interval: -0.09-37.3; p = 0.051). In MuSK-MG, an exploratory positive correlation with the MG Foundation of America (MGFA) classification was observed (ρ = 0.69, nominal p = 0.041). In generalized AChR-MG, median concentrations numerically decreased from 43.8 to 20.2 ng/mL after immunotherapy (p = 0.064), but no significant change was observed in the 15 patients whose paired samples were both within the standard range (p = 0.80).
DISCUSSION: These exploratory findings suggest that circulating utrophin may reflect disease-related biological changes in MG, although definitive conclusions regarding its biomarker utility cannot be drawn. Further validation in larger cohorts using analytically validated assays is warranted.
PMID:42868229 | DOI:10.1080/01616412.2026.2746411
Source: https://pubmed.ncbi.nlm.nih.gov/4286822 ... 4&v=2.20.1
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI
Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page

Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]
Bonne lecture...
Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page

Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]
Bonne lecture...





